In the agreement, Vaccinogen has obtained exclusive license to OncoVAX Active Specific Immunotherapy as well as an important component of the product TICE BCG. The vaccine is made from the patients’s own tumor and is injected back into the patient to effect an immune response against recurrence of that cancer.
Mr. Hanna, who has been working on cancer vaccines for more than 30 years, said: “This agreement represents a major step forward in defeating cancer by increasing the body’s immunity to it.”